(Q24246519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

title

Bisphosphonates for breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

N Pavlakis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Stockler

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

20 July 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

CD003474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Oral clodronate in breast cancer patients with bone metastases: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Controlled Clinical Study on the Use of Dichloromethylene Diphosphonate in Patients with Breast Carcinoma Metastasizing to the Skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Extended safety profile of oral clodronate after long-term use in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Cox's Regression Model for Counting Processes: A Large Sample Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Bone metastases and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

The clinical course of bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Identifying breast cancer patients at high risk for bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Bone and cancer: pathophysiology and treatment of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Mechanisms of osteolytic bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Overview of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Bisphosphonates: from the laboratory to the clinic and back again

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Methodology for treatment evaluation in patients with cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003474.PUB2

7 January 2021

10.1002/14651858.CD003474.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034900%20AND%20SRC:MED&resulttype=core&format=json

release_yr3tqjrd7ba45nbfznc3zqyn24

31 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yr3tqjrd7ba45nbfznc3zqyn24

24 November 2022

mapped directly with Wikidata item

1 reference